This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Di Napoli, M. Articles by Papa, F. Search for Related Content PubMed PubMed Citation Articles by Di Napoli, M. Articles by Papa, F. Related Collections Emergency treatment of Stroke

(Stroke. 2002;33:1763.)
© 2002 American Heart Association, Inc.

Original Contributions

Inflammation, Hemostatic Markers, and Antithrombotic Agents in Relation to Long-Term Risk of New Cardiovascular Events in First-Ever Ischemic Stroke Patients

Mario Di Napoli, MD Francesca Papa, MD for the Villa Pini Stroke Data Bank Investigators

From the Department of Neurology and Neurorehabilitation, Casa di Cura Villa Pini d’Abruzzo, Chieti, Italy.

Correspondence to Dr Mario Di Napoli, MD, Department of Neurology and Neurorehabilitation, Casa di Cura Villa Pini d’Abruzzo, Via dei Frentani, 228, 66100 Chieti, Italy. E-mail mariodinapoli{at}katamail.com

Background and Purpose— The measurement of markers of inflammation or thrombosis has been proposed as a method to improve the prediction of risk in patients with vascular disease. We evaluated the usefulness of these markers as predictors of cardiovascular events in ischemic stroke patients.

Methods— We analyzed levels of C-reactive protein (CRP), fibrinogen, and D-dimer within the first 24 hours after stroke onset in 473 first-ever ischemic stroke patients and determined the cumulative survival curves free of cardiovascular events in relation to the level of each of these markers according to the Kaplan-Meier method. We adjusted for possible confounding variables using a multivariate Cox proportional-hazards model.

Results— Patients in the highest tertiles of D-dimer, fibrinogen, and CRP were associated with an excess risk of new cardiovascular events of 36% (P=0.0134), 63% (P<0.0001), and 72% (P<0.0001), respectively, compared with patients in the lowest tertile. The patients in the highest tertile of CRP had 4 times the risk (hazard ratio, 4.04; P<0.0001) of a new cardiovascular event. Smoking, age, sex, and body mass index did not modify risk, and risk was independent of other confounding variables and of D-dimer and fibrinogen levels. The use of ticlopidine was associated with a significant risk reduction among patients with lower (86%, P=0.0159) and middle (69%, P<0.0001) levels of CRP, whereas a nonsignificant excess risk (27%, P=0.3896) was evident among those with the highest levels.

Conclusions— Elevated levels of CRP, more than of D-dimer and fibrinogen, are related to the risk of new cardiovascular events after ischemic stroke. The efficacy of antiplatelet therapy in secondary prevention appears to be directly related to level of inflammatory and thrombotic markers.

Key Words: C-reactive protein • fibrin D-dimers • inflammation • stroke, ischemic • ticlopidine

This article has been cited by other articles:

				G. J. del Zoppo, D. E. Levy, W. W. Wasiewski, A. M. Pancioli, A. M. Demchuk, J. Trammel, B. M. Demaerschalk, M. Kaste, G. W. Albers, and E. B. Ringelstein Hyperfibrinogenemia and Functional Outcome From Acute Ischemic Stroke Stroke, May 1, 2009; 40(5): 1687 - 1691. [Abstract] [Full Text] [PDF]

				M. Di Napoli and P. Singh Is Plasma Fibrinogen Useful in Evaluating Ischemic Stroke Patients?: Why, How, and When Stroke, May 1, 2009; 40(5): 1549 - 1552. [Full Text] [PDF]

				C. L. Carty, P. Heagerty, K. Nakayama, E. C. McClung, J. Lewis, D. Lum, E. Boespflug, C. McCloud-Gehring, B. R. Soleimani, J. Ranchalis, et al. Inflammatory Response After Influenza Vaccination in Men With and Without Carotid Artery Disease Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2738 - 2744. [Abstract] [Full Text] [PDF]

				P. Libby and P. M. Ridker Inflammation and Atherothrombosis: From Population Biology and Bench Research to Clinical Practice J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A33 - A46. [Abstract] [Full Text] [PDF]

				M. S. V. Elkind, W. Tai, K. Coates, M. C. Paik, and R. L. Sacco High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med, October 23, 2006; 166(19): 2073 - 2080. [Abstract] [Full Text] [PDF]

				P. Htun, S. Fateh-Moghadam, B. Tomandl, R. Handschu, K. Klinger, K. Stellos, C. Garlichs, W. Daniel, and M. Gawaz Course of Platelet Activation and Platelet-Leukocyte Interaction in Cerebrovascular Ischemia Stroke, September 1, 2006; 37(9): 2283 - 2287. [Abstract] [Full Text] [PDF]

				M. J. O'Donnell, E. Berge, and P. M. Sandset Are There Patients With Acute Ischemic Stroke and Atrial Fibrillation That Benefit From Low Molecular Weight Heparin? Stroke, February 1, 2006; 37(2): 452 - 455. [Abstract] [Full Text] [PDF]

				M. Di Napoli, M. Schwaninger, R. Cappelli, E. Ceccarelli, G. Di Gianfilippo, C. Donati, H. C.A. Emsley, S. Forconi, S. J. Hopkins, L. Masotti, et al. Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke: A Statement for Health Care Professionals From the CRP Pooling Project Members Stroke, June 1, 2005; 36(6): 1316 - 1329. [Abstract] [Full Text] [PDF]

				K. Sander, D. Sander, H. Audebert, and R. L. Haberl Systemic Inflammatory Response Depends on Initial Stroke Severity but Is Attenuated by Successful Thrombolysis * Response Stroke, February 1, 2005; 36(2): 232 - 232. [Full Text] [PDF]

				P. M. Rothwell, S. C. Howard, D. A. Power, S. A. Gutnikov, A. Algra, J. van Gijn, T. G. Clark, M. F.G. Murphy, C. P. Warlow, and for the Cerebrovascular Cohort Studies Collaborati Fibrinogen Concentration and Risk of Ischemic Stroke and Acute Coronary Events in 5113 Patients With Transient Ischemic Attack and Minor Ischemic Stroke Stroke, October 1, 2004; 35(10): 2300 - 2305. [Abstract] [Full Text] [PDF]

				C. Wojcik and M. Di Napoli Ubiquitin-Proteasome System and Proteasome Inhibition: New Strategies in Stroke Therapy Stroke, June 1, 2004; 35(6): 1506 - 1518. [Abstract] [Full Text] [PDF]

				M. Di Napoli and A. Arakelyan POEMS Syndrome, Fibrinogen, and Ischemic Stroke: A Critical Point of View Arch Neurol, January 1, 2004; 61(1): 155 - 155. [Full Text] [PDF]

				M. Di Napoli and F. Papa Angiotensin-Converting Enzyme Inhibitor Use Is Associated With Reduced Plasma Concentration of C-Reactive Protein in Patients With First-Ever Ischemic Stroke Stroke, December 1, 2003; 34(12): 2922 - 2929. [Abstract] [Full Text] [PDF]

				M. Di Napoli and F. Papa Association Between Blood Pressure and C-Reactive Protein Levels in Acute Ischemic Stroke Hypertension, December 1, 2003; 42(6): 1117 - 1123. [Abstract] [Full Text] [PDF]

				M. Di Napoli Editorial Comment--C-Reactive Protein and Vascular Risk in Stroke Patients: Potential Use for the Future Stroke, October 1, 2003; 34(10): 2468 - 2470. [Full Text] [PDF]

				P. J. Lindsberg and A. J. Grau Inflammation and Infections as Risk Factors for Ischemic Stroke Stroke, October 1, 2003; 34(10): 2518 - 2532. [Abstract] [Full Text] [PDF]

				M. Di Napoli Editorial Comment--How to Search for the Role of Genetic Polymorphisms in Stroke: Theory Versus Practice Stroke, August 1, 2003; 34(8): 1869 - 1870. [Full Text] [PDF]

				C.D. Garlichs, S. Kozina, S. Fateh-Moghadam, B. Tomandl, C. Stumpf, S. Eskafi, D. Raaz, A. Schmeisser, A. Yilmaz, J. Ludwig, et al. Upregulation of CD40-CD40 Ligand (CD154) in Patients With Acute Cerebral Ischemia Stroke, June 1, 2003; 34(6): 1412 - 1418. [Abstract] [Full Text] [PDF]

				K W Muir Magnesium in stroke treatment Postgrad. Med. J., November 1, 2002; 78(925): 641 - 645. [Abstract] [Full Text] [PDF]

				I. Iyigun, M. Di Napoli, and F. Papa C-Reactive Protein in Ischemic Stroke * Response Stroke, September 1, 2002; 33(9): 2146 - 2147. [Full Text] [PDF]